Solid Biosciences Inc. Finance Lease, Liability, Undiscounted Excess Amount
Solid Biosciences Inc. (SLDB) had Finance Lease, Liability, Undiscounted Excess Amount of $242.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-13.
Discontinued › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2024-03-13
- 2023-12-31: Finance Lease, Liability, Undiscounted Excess Amount $242.00K.
- 2022-12-31: Finance Lease, Liability, Undiscounted Excess Amount $199.00K.
- 2021-12-31: Finance Lease, Liability, Undiscounted Excess Amount $51.00K.
- 2020-12-31: Finance Lease, Liability, Undiscounted Excess Amount $119.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2023-12-31 | $242.00K 10-K · filed 2024-03-13 |
| 2022-12-31 | $199.00K 10-K · filed 2023-03-23 |
| 2021-12-31 | $51.00K 10-K · filed 2022-03-14 |
| 2020-12-31 | $119.00K 10-K · filed 2021-03-15 |
| 2019-12-31 | $209.00K 10-K · filed 2020-03-12 |
| 2019-09-30 | $234.00K 10-Q · filed 2019-11-12 |
| 2019-06-30 | $261.00K 10-Q · filed 2019-08-14 |
| 2019-03-31 | $252.00K 10-Q · filed 2019-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |